Zennova Pharmaceuticals, a Princeton, NJ-based development stage pharmaceutical company focused on complex ophthalmic suspensions and emulsions, hosted a dedication for its manufacturing plant and R&D center on January 11, 2023 in Chengdu, China. The construction of the multi-dosage formulation center signifies completion of a key company milestone in the company’s pathway towards globalization.
“The capability to produce high-quality drugs during 2023 will be crucial to long-term growth initiatives,” said Dahai Guo, president, Zennova.
According to the company, recent noteworthy accomplishments helping to clear the pathway to pipeline asset approvals include U.S. FDA submission of Zenno-01 to FDA, agency audit of Zennova’s New York laboratories, and a successful FDA audit of current U.S.-based CDMO and analytical partners.
Phase I (300,000 sq. ft.) of Zennova’s manufacturing facility and R&D center features state-of-the-art production capabilities and consists of manufacturing, R&D, warehousing, and administrative buildings. The facilities’ interior includes three/four stories in the R&D, Quality Assurance, and Control buildings. The facility, equipment, and staff will ensure global product and logistical quality and is anticipated to meet U.S. FDA, EU, NMPA and other regulated market quality standards. Zennova will enter international markets via technology-oriented CDMO businesses. Phase II will include an additional 500,000 sq. ft.
